What should you know about ductal carcinoma her2 positive?

Ductal carcinoma describes cancer that begins in a milk duct. HER2 is a protein involved in cell growth; a positive result means the tumour has increased HER2 activity or expression on testing. The result is one part of the diagnosis alongside tumour size, grade, lymph-node findings, hormone-receptor status, and whether disease has spread. A HER2 result does not predict an individual outcome on its own. If the wording comes from a biopsy report, the pathology team can explain the test method and any uncertainty.

Start by reviewing the pathology report with a breast specialist. A mammogram and breast biopsy may be used to define the area and confirm the diagnosis. Treatment can involve surgery such as lumpectomy or mastectomy, medicines that target HER2, chemotherapy, radiotherapy, hormone therapy when hormone receptors are present, or a combination. The order depends on the tumour features, imaging, overall health, and personal preferences. Ask for a clear plan, including why each treatment is recommended and how side effects will be monitored.

Tell your treatment team promptly about fever, new breathlessness, chest pain, severe diarrhoea or vomiting, dehydration, an infusion reaction, or swelling and pain after surgery. Seek emergency help for severe breathing difficulty, fainting, sudden weakness, or facial swelling. Bring a complete medicine list to appointments, including supplements, so possible interactions can be checked.

Ask whether HER2 was tested by immunohistochemistry or another method, whether repeat testing is needed, and how hormone-receptor results affect the plan. Ask what surgery is suitable, whether radiotherapy is recommended, how heart health will be monitored with certain medicines, and whom to call about side effects.